NAVB [AMEX]
Navidea Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.40 Insider Own27.80% Shs Outstand30.17M Perf Week5.81%
Market Cap23.25M Forward P/E- EPS next Y-0.16 Insider Trans0.00% Shs Float21.92M Perf Month-17.17%
Income-11.70M PEG- EPS next Q-0.03 Inst Own5.40% Short Float1.02% Perf Quarter-9.70%
Sales0.50M P/S46.49 EPS this Y16.10% Inst Trans-4.49% Short Ratio0.60 Perf Half Y-41.84%
Book/sh0.00 P/B- EPS next Y46.70% ROA-119.90% Target Price5.00 Perf Year-51.19%
Cash/sh0.15 P/C5.53 EPS next 5Y- ROE-333.90% 52W Range0.72 - 2.19 Perf YTD-18.00%
Dividend- P/FCF- EPS past 5Y15.90% ROI- 52W High-62.56% Beta1.47
Dividend %- Quick Ratio1.00 Sales past 5Y-36.10% Gross Margin- 52W Low13.89% ATR0.10
Employees11 Current Ratio1.00 Sales Q/Q-50.00% Oper. Margin- RSI (14)44.93 Volatility12.42% 11.57%
OptionableYes Debt/Eq- EPS Q/Q-7.80% Profit Margin- Rel Volume0.04 Prev Close0.82
ShortableYes LT Debt/Eq- EarningsMay 12 AMC Payout- Avg Volume374.59K Price0.82
Recom2.00 SMA20-11.84% SMA50-5.62% SMA200-32.81% Volume15,746 Change0.00%
Nov-13-13Reiterated Aegis Capital Hold $3 → $2
Nov-07-13Reiterated Ladenburg Thalmann Buy $7.50 → $3
Jan-24-13Initiated Burrill Institutional Research Mkt Outperform $5
Jan-22-13Initiated Aegis Capital Hold $3
Sep-11-12Reiterated WBB Securities Strong Buy $9 → $7
Sep-11-12Reiterated Rodman & Renshaw Mkt Outperform $7 → $6
Sep-11-12Reiterated Ladenburg Thalmann Buy $6.25 → $7.50
May-12-22 07:30AM  
May-05-22 07:30AM  
Apr-20-22 06:58AM  
06:55AM  
Apr-18-22 04:01PM  
Apr-12-22 04:05PM  
04:01PM  
Apr-07-22 07:30AM  
Mar-23-22 03:44PM  
03:09PM  
Mar-16-22 07:30AM  
Feb-07-22 07:30AM  
Feb-03-22 04:01PM  
Dec-16-21 04:01PM  
07:58AM  
Dec-15-21 04:02PM  
04:01PM  
Dec-13-21 07:30AM  
Dec-09-21 04:01PM  
Nov-04-21 03:01PM  
Nov-03-21 04:01PM  
Oct-26-21 05:22PM  
Oct-14-21 07:30AM  
Sep-27-21 07:30AM  
Sep-20-21 09:07AM  
Sep-17-21 07:30AM  
Aug-11-21 05:15PM  
04:01PM  
Aug-04-21 07:30AM  
Jul-19-21 07:30AM  
Jul-15-21 07:30AM  
Jun-24-21 07:00AM  
Jun-14-21 07:32PM  
May-19-21 07:30AM  
May-11-21 04:01PM  
03:15PM  
07:30AM  
May-05-21 08:00AM  
May-04-21 07:30AM  
Apr-15-21 07:30AM  
Mar-24-21 04:21PM  
02:45PM  
Mar-17-21 07:30AM  
Mar-02-21 04:01PM  
07:30AM  
Feb-09-21 08:09AM  
Feb-08-21 04:05PM  
Jan-07-21 07:30AM  
Dec-28-20 07:30AM  
Dec-08-20 09:51AM  
Nov-26-20 06:34PM  
Nov-12-20 04:02PM  
04:01PM  
03:15PM  
Nov-05-20 04:01PM  
Oct-29-20 12:35PM  
Oct-22-20 07:30AM  
Oct-09-20 07:30AM  
Sep-28-20 07:30AM  
Sep-08-20 04:05PM  
Sep-02-20 04:05PM  
Aug-31-20 05:00PM  
Aug-24-20 04:05PM  
03:01PM  
Aug-13-20 04:09PM  
Aug-10-20 09:08AM  
07:30AM  
Aug-06-20 04:15PM  
Aug-05-20 07:30AM  
Jun-25-20 03:50AM  
Jun-17-20 09:43AM  
Jun-15-20 08:00AM  
Jun-09-20 07:30AM  
Jun-03-20 07:30AM  
May-26-20 10:11AM  
May-22-20 08:35AM  
07:10AM  
May-21-20 04:30PM  
May-14-20 04:01PM  
May-11-20 07:30AM  
May-07-20 07:00AM  
Apr-22-20 07:30AM  
Apr-21-20 08:52AM  
Mar-31-20 07:30AM  
Mar-24-20 04:19PM  
Mar-20-20 07:00AM  
Mar-11-20 04:05PM  
03:00PM  
Mar-04-20 08:00AM  
Feb-21-20 08:42AM  
Feb-14-20 11:56AM  
07:28AM  
Feb-12-20 09:20AM  
Dec-30-19 05:19PM  
Dec-14-19 09:41AM  
Dec-06-19 06:23PM  
Dec-05-19 03:45PM  
Dec-02-19 02:08PM  
Nov-19-19 10:41PM  
Nov-14-19 08:30AM  
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Witter Malcolm GDirectorSep 17Buy1.6020,00031,95298,257Sep 17 04:41 PM
Witter Malcolm GDirectorJul 26Buy1.7015,00025,47078,257Jul 26 04:38 PM